NCT00365053 2018-06-07PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By SurgeryNational Cancer Institute (NCI)Phase 2 Completed13 enrolled 7 charts